Old drugs, new hope: combo tackles relapsed leukemia after transplant

NCT ID NCT02312102

Completed Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two chemotherapy drugs, bortezomib (Velcade) and lenalidomide (Revlimid), in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) had returned after a stem cell transplant. The main goal was to find the safest dose and see if the combo could reduce cancer cells. While promising, the study is small and early, so more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib (Velcade) and lenalidomide (Revlimid)
What this could lead to: If successful, this combination could offer a new treatment option for people whose AML or MDS has returned after a stem cell transplant.
What could go wrong: This is a very early, small Phase 1 trial with only 22 participants, so results may not apply broadly. The drugs also have known side effects like low blood counts and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.